Whereas both RASA2-KO and control CAR T cells efficiently killed leukaemia cells expressing high CD19 levels, RASA2 inactivation augmented the in vitro killing of leukaemia target cells versus control T cells in the context of low antigen expression (Fig. 2h and Extended Data Fig. 4e,f). The gene discussed is CD19; the disease is leukemia.